Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/12249
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMargiotta-Casaluci, L-
dc.contributor.authorOwen, SF-
dc.contributor.authorHuerta, B-
dc.contributor.authorRodríguez-Mozaz, S-
dc.contributor.authorKugathas, S-
dc.contributor.authorBarceló, D-
dc.contributor.authorRand-Weaver, M-
dc.contributor.authorSumpter, JP-
dc.date.accessioned2016-03-03T12:43:06Z-
dc.date.available2016-02-26-
dc.date.available2016-03-03T12:43:06Z-
dc.date.issued2016-
dc.identifier.citationScientific Reports, 6: 21978, (2016)en_US
dc.identifier.issn2045-2322-
dc.identifier.urihttps://www.nature.com/articles/srep21978-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/12249-
dc.description.abstractThe Adverse Outcome Pathway (AOP) framework represents a valuable conceptual tool to systematically integrate existing toxicological knowledge from a mechanistic perspective to facilitate predictions of chemical-induced effects across species. However, its application for decision-making requires the transition from qualitative to quantitative AOP (qAOP). Here we used a fish model and the synthetic glucocorticoid beclomethasone dipropionate (BDP) to investigate the role of chemical-specific properties, pharmacokinetics, and internal exposure dynamics in the development of qAOPs. We generated a qAOP network based on drug plasma concentrations and focused on immunodepression, skin androgenisation, disruption of gluconeogenesis and reproductive performance. We showed that internal exposure dynamics and chemical-specific properties influence the development of qAOPs and their predictive power. Comparing the effects of two different glucocorticoids, we highlight how relatively similar in vitro hazard-based indicators can lead to different in vivo risk. This discrepancy can be predicted by their different uptake potential, pharmacokinetic (PK) and pharmacodynamic (PD) profiles. We recommend that the development phase of qAOPs should include the application of species-species uptake and physiologically-based PK/PD models. This integration will significantly enhance the predictive power, enabling a more accurate assessment of the risk and the reliable transferability of qAOPs across chemicals.en_US
dc.description.sponsorshipThis work was funded by a Biotechnology and Biological Sciences Research Council (BBSRC) Research Grant (BB/100646X/1), co-funded by the AstraZeneca Global Safety, Health and Environment research programme, to JPS and MR-W supporting LM-C.en_US
dc.language.isoenen_US
dc.publisherNature Publishing Groupen_US
dc.subjectToxicologyen_US
dc.subjectadverse outcome pathwayen_US
dc.subjectfish biologyen_US
dc.subjectdrug safetyen_US
dc.subjectenvironmental risk assessmenten_US
dc.subjectpharmaceuticalsen_US
dc.titleInternal exposure dynamics drive the Adverse Outcome Pathways of synthetic glucocorticoids in fishen_US
dc.typeArticleen_US
dc.identifier.doihttps//doi.org/10.1038/srep21978-
dc.relation.isPartOfScientific Reports-
pubs.publication-statusPublished online-
pubs.publication-statusPublished online-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
Fulltext.pdf1.25 MBHTMLView/Open


Items in BURA are protected by copyright, with all rights reserved, unless otherwise indicated.